INVA Innoviva Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: INVA

Price (delayed)

$16.1

Market cap

$1.12B

P/E Ratio

5.85

Dividend/share

N/A

EPS

$2.75

Enterprise value

$1.47B

Innoviva, Inc. is a healthcare focused asset management company. The Company intends to participate in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva operates in the United States.

Highlights
The company's EPS rose by 22% YoY and by 10% QoQ
The gross profit is up by 22% YoY and by 6% from the previous quarter
The stock's price to earnings (P/E) is 34% less than its 5-year quarterly average of 8.8 but 17% more than its last 4 quarters average of 5.0
Innoviva's quick ratio has plunged by 72% from the previous quarter and by 70% YoY
The equity has declined by 48% since the previous quarter and by 28% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.inva.com
Peers: ONTX OPK

Key stats

What are the main financial stats of INVA
Market
Shares outstanding
69.49M
Market cap
$1.12B
Enterprise value
$1.47B
Valuations
Price to earnings (P/E)
5.85
Price to book (P/B)
4.95
Price to sales (P/S)
3.9
EV/EBIT
4.15
EV/EBITDA
3.99
EV/Sales
4.01
Earnings
Revenue
$365.49M
EBIT
$353.56M
EBITDA
$367.4M
Free cash flow
$328.56M
Per share
EPS
$2.75
Free cash flow per share
$3.72
Book value per share
$3.25
Revenue per share
$4.13
TBVPS
$8.92
Balance sheet
Total assets
$789.15M
Total liabilities
$395.41M
Debt
$389.99M
Equity
$329.78M
Working capital
$142.89M
Liquidity
Debt to equity
1.18
Current ratio
27.6
Quick ratio
27.47
Net debt/EBITDA
0.94
Margins
EBITDA margin
100.5%
Gross margin
100%
Net margin
72.6%
Operating margin
94.5%
Efficiency
Return on assets
27.9%
Return on equity
53.3%
Return on invested capital
33.1%
Return on capital employed
45.1%
Return on sales
96.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

INVA stock price

How has the Innoviva stock price performed over time
Intraday
1.19%
1 week
-2.48%
1 month
-5.85%
1 year
67.19%
YTD
29.94%
QTD
-3.65%

Financial performance

How have Innoviva's revenue and profit performed over time
Revenue
$365.49M
Gross profit
$365.49M
Operating income
$345.24M
Net income
$265.19M
Gross margin
100%
Net margin
72.6%
The gross profit is up by 22% YoY and by 6% from the previous quarter
The revenue has grown by 22% YoY and by 6% from the previous quarter
INVA's operating income is up by 21% YoY and by 6% QoQ
INVA's net income is up by 16% year-on-year and by 4.8% since the previous quarter

Growth

What is Innoviva's growth rate over time

Valuation

What is Innoviva stock price valuation
P/E
5.85
P/B
4.95
P/S
3.9
EV/EBIT
4.15
EV/EBITDA
3.99
EV/Sales
4.01
The stock's price to earnings (P/E) is 34% less than its 5-year quarterly average of 8.8 but 17% more than its last 4 quarters average of 5.0
The company's EPS rose by 22% YoY and by 10% QoQ
The P/B is 90% above the last 4 quarters average of 2.6
The equity has declined by 48% since the previous quarter and by 28% year-on-year
The P/S is 33% lower than the 5-year quarterly average of 5.8 but 15% higher than the last 4 quarters average of 3.4
The revenue has grown by 22% YoY and by 6% from the previous quarter

Efficiency

How efficient is Innoviva business performance
INVA's return on equity is down by 17% year-on-year but it is up by 12% since the previous quarter
The return on invested capital has declined by 9% year-on-year
INVA's ROA is up by 7% from the previous quarter but it is down by 6% YoY
The company's return on sales fell by 5% YoY

Dividends

What is INVA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INVA.

Financial health

How did Innoviva financials performed over time
The total assets is 100% greater than the total liabilities
Innoviva's quick ratio has plunged by 72% from the previous quarter and by 70% YoY
The company's current ratio has shrunk by 72% QoQ and by 70% YoY
The debt is 18% more than the equity
The debt to equity has surged by 93% since the previous quarter and by 42% year-on-year
The equity has declined by 48% since the previous quarter and by 28% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.